Next Article in Journal
Covering Aluminum Oxide Nanoparticles with Biocompatible Materials to Efficiently Deliver Subunit Vaccines
Previous Article in Journal
Use of a Novel Enhanced DNA Vaccine Vector for Preclinical Virus Vaccine Investigation
Article

An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies

1
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
2
The Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
3
Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
*
Authors to whom correspondence should be addressed.
Equal contribution.
Vaccines 2019, 7(2), 51; https://doi.org/10.3390/vaccines7020051
Received: 6 May 2019 / Revised: 6 June 2019 / Accepted: 10 June 2019 / Published: 14 June 2019
(This article belongs to the Section Vaccines against Infectious Diseases)
Human cytomegalovirus (CMV) is a highly prevalent pathogen with ~60%–90% seropositivity in adults. CMV can contribute to organ rejection in transplant recipients and is a major cause of birth defects in newborns. Currently, there are no approved vaccines against CMV. The epitope of a CMV neutralizing monoclonal antibody against a conserved region of the envelope protein gH provided the basis for a new CMV vaccine design. We exploited the influenza A virus as a vaccine platform due to the highly immunogenic head domain of its hemagglutinin envelope protein. Influenza A variants were engineered by reverse genetics to express the epitope of an anti-CMV gH neutralizing antibody that recognizes native gH into the hemagglutinin antigenic Sa site. We determined that the recombinant influenza variants expressing 7, 10, or 13 residues of the anti-gH neutralizing antibody epitope were recognized and neutralized by the anti-gH antibody 10C10. Mice vaccinated with the influenza/CMV chimeric viruses induced CMV-specific antibodies that recognized the native gH protein and inhibited virus infection. In fact, the influenza variants expressing 7–13 gH residues neutralized a CMV infection at ~60% following two immunizations with variants expressing the 13 residue gH peptide produced the highest levels of neutralization. Collectively, our study demonstrates that a variant influenza virus inserted with a gH peptide can generate a humoral response that limits a CMV infection. View Full-Text
Keywords: influenza virus; human cytomegalovirus; vaccine; humoral immunity; neutralization; hemagglutinin; gH envelope protein influenza virus; human cytomegalovirus; vaccine; humoral immunity; neutralization; hemagglutinin; gH envelope protein
Show Figures

Figure 1

MDPI and ACS Style

Behzadi, M.A.; Stein, K.R.; Bermúdez-González, M.C.; Simon, V.; Nachbagauer, R.; Tortorella, D. An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies. Vaccines 2019, 7, 51. https://doi.org/10.3390/vaccines7020051

AMA Style

Behzadi MA, Stein KR, Bermúdez-González MC, Simon V, Nachbagauer R, Tortorella D. An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies. Vaccines. 2019; 7(2):51. https://doi.org/10.3390/vaccines7020051

Chicago/Turabian Style

Behzadi, Mohammad A., Kathryn R. Stein, Maria C. Bermúdez-González, Viviana Simon, Raffael Nachbagauer, and Domenico Tortorella. 2019. "An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies" Vaccines 7, no. 2: 51. https://doi.org/10.3390/vaccines7020051

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop